

TABLE OF CONTENTS		
Section	Title	Page Nos.
Chapter -1 INTRODUCTION		
1.1.	Gastroenteritis	2
1.1.1.	Enteric pathogens- <i>Vibrio</i> spp. and <i>Shigella</i> spp.	3
1.1.1.1.	<i>Vibrio</i> spp. and their outbreaks	3
1.1.1.2.	<i>Shigella</i> spp. and their outbreaks	6
1.2.	Treatment complications in <i>Vibrio</i> and <i>Shigella</i> infection due to the problem of drug resistance	7
1.3.	Quinolone class of antibiotics	10
1.3.1	Targets of quinolones in bacterial cell and their mode of activity	12
1.3.2	Quinolone resistance mechanisms	15
1.3.2.1	Mutations in topoisomerase genes (chromosome-borne)	15
1.3.2.2.	Efflux pumps (chromosome- and plasmid-borne)	17
1.3.2.3.	<i>qnr</i> genes (chromosome- and plasmid-borne)	18
1.3.2.4.	Ciprofloxacin modifying enzyme (AAC (6') -Ib-cr)	20
1.3.3.	Databases available for quinolone resistance genes	21
1.4.	Prevalence of quinolone resistance in <i>Vibrio</i> and <i>Shigella</i> spp.	21
1.5.	Need for this study	30
1.6.	Aims and Objectives	30
Chapter -2 MATERIALS AND METHODS		
2.1.	Bacterial isolates/strains	33

2.2.	Triplex PCR assay for rapid identification of <i>Vibrio</i> species	33
2.3.	Antibiogram tests for clinical isolates	36
2.4.	Minimum inhibitory concentration (MIC) assay	36
2.4.1.	MIC assay using Ezy MIC strip method	36
2.4.2.	MIC assay using two-fold dilution method	37
2.4.2.1.	MIC assay of native <i>V. fluvialis</i> isolates and <i>E. coli</i> JM109 transformants	37
2.4.2.2.	MIC assay of QnrVC5 recombinants	38
2.4.2.3.	MIC assay of <i>V. fluvialis</i> isolates in presence of Peptide nucleic acid (PNA)	38
2.5.	Isolation and the analysis of genomic and plasmid DNA from the clinical isolates	39
2.5.1.	Genomic DNA isolation from the clinical isolates	39
2.5.2.	Plasmid DNA isolation from clinical isolates	40
2.5.3.	Plasmid DNA isolation using QIAGEN plasmid purification kit	41
2.6.	Polymerase chain reaction (PCR)	42
2.6.1.	PCR screening of quinolone resistance genes	42
2.6.2.	PCR amplification of QRDR regions of topoisomerase genes	42
2.7.	DNA sequencing, sequence analysis and GenBank submissions	43
2.8.	Cloning and expression of <i>qnrVC5</i> gene in heterologous <i>E. coli</i> host	43
2.8.1.	PCR amplification of <i>qnrVC5</i> gene	44
2.8.2.	Purification of PCR (<i>qnrVC5</i>) products using Qiagen QIA quick PCR purification kit	44
2.8.3.	Restriction digestion of DNA samples	48
2.8.4.	Phenol chloroform purification of restricted digested	49

	samples of pET28a vector and <i>qnrVC5</i> insert	
2.8.5.	Ligation of <i>qnrVC5</i> and pET28a	50
2.8.6.	Preparation of Electrocompetent (EC) cells	50
2.8.7.	Electroporation in <i>E. coli</i>	51
2.8.8.	Preparation of master plate for transformants	51
2.8.9.	Small scale preparation (Miniprep) of plasmid DNA from recombinant clones	52
2.8.10.	Confirming the authenticity of recombinant pET28- <i>qnrVC5</i> clones	52
2.8.10.1.	PCR of <i>qnrVC5</i> gene	52
2.8.10.2.	Restriction analysis of clones using <i>NheI</i> enzyme	52
2.8.10.3.	DNA sequence analysis of clones	53
2.8.11.	Preparation of calcium chloride (CaCl ₂) chemically competent cells	53
2.8.12.	Transformation of <i>E.coli</i> in chemically competent cells	53
2.8.13.	Expression of QnrVC5 protein	54
2.9.	Total RNA isolation from bacteria using QIAGEN RNeasy mini kit	56
2.10.	Expression of the putative resistance genes in the native isolates and their transformants	57
2.11.	Mutant prevention concentration (MPC) assay	58
2.12	<i>In silico</i> analysis	59
<p style="text-align: center;">Chapter -3</p> <p style="text-align: center;">BACTERIAL IDENTIFICATION AND ANTIBIOTIC SUSCEPTIBILITY OF CLINICAL ISOLATES OF <i>VIBRIO</i> AND <i>SHIGELLA</i> SPECIES</p>		
3.1.	Introduction	61
3.2.	Results	63
3.2.1.	Bacterial strains and their identification	63

3.2.2.	Antimicrobial susceptibility of bacterial isolates	67
3.2.3.	Quinolone-resistance phenotypes in the isolates of <i>Vibrio</i> and <i>Shigella</i> spp.	69
3.3.	Discussion	76
<p style="text-align: center;">Chapter – 4</p> <p style="text-align: center;">GENOTYPIC CHARACTERIZATION OF QUINOLONE RESISTANT ISOLATES OF <i>VIBRIO</i> AND <i>SHIGELLA</i> ISOLATES AND CORRELATION WITH THEIR PHENOTYPE</p>		
4.1.	Introduction	80
4.2.	Results	82
4.2.1.	PMQR determinants found in the quinolone-resistant isolates and their expression in the native isolates	82
4.2.2.	Mutations in QRDR region of topoisomerase genes and their role in quinolone resistance	84
4.2.3.	GenBank submissions	89
4.3.	Discussion	94
<p style="text-align: center;">Chapter – 5</p> <p style="text-align: center;">CHARACTERIZATION OF <i>VIBRIO FLUVIALIS qnrVC5</i> GENE IN NATIVE AND HETEROLOGOUS HOSTS: SYNERGY OF <i>qnrVC5</i> WITH OTHER DETERMINANTS IN CONFERRING QUINOLONE RESISTANCE</p>		
5.1.	Introduction	97
5.2.	Results	99
5.2.1.	Presence of <i>qnrVC5</i> gene in <i>V. fluvialis</i> isolates, characterization of the gene and its flanking genetic environment	99
5.2.2.	Sequence analysis, homology and structure prediction for <i>qnrVC5</i> gene/protein	101
5.2.3.	Contribution of <i>qnrVC5</i> gene in quinolone resistance of their native <i>V. fluvialis</i> host	102
5.2.4.	Contribution of <i>qnrVC5</i> gene in quinolone	103

	resistance of <i>E.coli</i> transformants	
5.2.5.	Expression of <i>qnrVC5</i> gene in the native <i>V. fluvialis</i> host and <i>E. coli</i> transformants	107
5.2.6.	Effect of PNA against <i>qnrVC5</i> gene in native <i>V. fluvialis</i> host	108
5.2.7.	Gene cloning and recombinant protein expression	109
5.2.8.	Elevation of MIC for quinolones in <i>qnrVC5</i> recombinants	110
5.3.	Discussion	111
	SUMMARY AND CONCLUSION	115
	REFERENCES	120
	APPENDICES	136
	LIST OF PUBLICATIONS	147
	REPRINTS OF PUBLICATIONS AND POSTERS	149